← All indications
Leukemia-Lymphoma, Adult T-Cell
Aggressive T-Cell malignancy with adult onset, caused by HUMAN T-LYMPHOTROPIC VIRUS 1. It is endemic in Japan, the Caribbean basin, Southeastern United States, Hawaii, and parts of Central and South America and sub-Saharan Africa.
Drugs by status
Approved for this indication (1)
Phase 4 trials (5)
Phase 3 trials (1)
Phase 2 trials (86)
- allopurinol
- cladribine
- azacitidine
- methylprednisolone
- mercaptopurine
- ibritumomab tiuxetan
- aminolevulinic acid
- astx660
- urea
- sorafenib
- venetoclax
- belinostat
- bendamustine
- brentuximab vedotin
- busulfan
- lenalidomide
- temsirolimus
- clofarabine
- denileukin diftitox
- n-(4-hydroxyphenyl)all-trans retinamide
- gemcitabine
- oblimersen sodium
- aciclovir
- tacrolimus
- imatinib
- naltrexone
- aldesleukin
- beclomethasone
- imtox-25
- Filgrastim
- +56 more
Phase 1 trials (41)
- fau
- decitabine
- 7-hydroxystaurosporine
- alvespimycin
- autologous cd19car-cd28-cd3zeta-egfrt-expressing tcm-enriched t cells
- bryostatin
- irinotecan
- carfilzomib
- cilengitide
- devimistat
- dc vaccine
- duvelisib
- entinostat
- paclitaxel
- ar-42
- in111 anti-cd45 monoclonal antibody bc8
- autologous natural killer cells
- ispinesib
- ixazomib
- methoxyamine
- morab-004
- mrg-106
- ibrutinib
- perifosine
- sunitinib
- interleukin-15
- ro4929097
- bevacizumab
- tanespimycin
- dasatinib
- +11 more
Organizations
Organization Involved with Phase 4 Indications (1)
Organization Involved with Phase 3 Indications (3)
Organization Involved with Phase 2 Indications (43)
- Daiichi Sankyo
- Seattle Genetics
- Celgene
- Merck
- Novartis
- HUYA Bioscience International
- Kyowa Hakko Kirin
- Otsuka
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- National Heart, Lung, and Blood Institute (NHLBI)
- AIDS Malignancy Consortium
- Cancer and Leukemia Group B (CALGB)
- Case Western Reserve University
- Cornell University
- Eastern Cooperative Oncology Group
- Duke University
- University of Washington
- Kumamoto University
- Northwestern University
- Ohio State University
- Okayama University
- Rutgers University
- Southwest Oncology Group
- Stanford University
- Thomas Jefferson University
- University of Medicine and Dentistry of New Jersey
- University of Miami
- University of Nebraska
- University of Rochester
- +13 more
Organization Involved with Phase 1 Indications (15)
- Millennium Pharmaceuticals
- Amgen
- Morphotek
- Arno Therapeutics
- Erimos Pharmaceuticals
- miRagen Therapeutics, Inc.
- Huazhong University of Science and Technology
- University of Pittsburgh
- Johns Hopkins University
- Wake Forest University
- Wayne State University
- University of Colorado, Denver
- University of Wisconsin
- University of Alabama, Birmingham
- Wuhan Bio-Raid Biotechnology Co, Ltd. China
Organization Involved with Other Experimental Indications (1)